Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912…

Overview of attention for article published in Alzheimer's Research & Therapy, August 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 19 news stories from 10 outlets.

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Annual Results/Annual Report Vivoryon Therapeutics N.V.: Vivoryon…

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Annual Results/Annual Report Vivoryon Therapeutics N.V.: Vivoryon…

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Annual Results/Annual Report Vivoryon Therapeutics N.V.: Vivoryon…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 15 additional news stories.